Reducing the ecological footprint of pharmaceutical usage: Linkages between healthcare practices and the environment

Green and Sustainable Pharmacy

Volumn , Issue , 2010, Pages 77-102

  Daughton, Christian G ^a   Ruhoy, Ilene S ^b  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b TOURO UNIVERSITY NEVADA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892029285     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-05199-9_6     Document Type: Chapter

References (107)

1. Adam GIR, Sanders R, Jonsson J (1999) The development of pharmacogenomic models to predict drug response. Trends Biotechnol 17, 30-33
2. Anonymous (2008) List of withdrawn drugs. Wikipedia. http://en.wikipedia. org/wiki/List-of-withdrawn-drugs
3. Baird D (2003) Veterinary medicines in natural ecosystems: Assessing the risks. J Vet Pharmacol Therapeut 26, 28-29
4. Bajcar JM, Kennie N, Einarson TR (2005) Collaborative medication management in a team-based primary care practice: An explanatory conceptual framework. Res Social Adm Pharm 1, 408-429
5. BCG (December 2003) The hidden epidemic: Finding a cure for unfilled prescriptions and missed doses. The Boston Consulting Group. http://www.bcg.com/impact-expertise/publications/files/Hidden-Epidemic-Finding- Cure-Unfulfilled-Rx-Missed-Doses-Dec2003.pdf
6. Berenguer B, La Casa C, de la Matta MJ, Martin-Calero MJ (2004) Pharmaceutical care: Past, present and future. Curr Pharm Des 10, 3931-3946
7. Bernini P, Bertini I, Luchinat C, Nepi S, Saccenti E, Schäfer H, Schütz B, Spraul M, Tenori L (2009) Individual human phenotypes in metabolic space and time. J Proteome Res 8, 4264-4271
8. Borisy AA, Elliott PJ, Hurst NW, Lee MS, LehÃr J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockwell BR, Keith CT (2003) Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 100, 7977-7982
9. Boxall ABA (2002) The environmental side effects of medication-How are human and veterinary medicines in soils and water bodies affecting human and environmental health? Embo Reports 5, 1110-1116
10. Carbone AL, Song M, Uhrich KE (2008) Iodinated salicylate-based poly(anhydride-esters) as radiopaque biomaterials. Biomacromolecules 9, 1604-1612
11. Clark J, Summerton L, Smith E, Kampa E, Vidaurre R, Touraud E (2007) Discussion document on eco-pharmacostewardship. KNAPPE: Knowledge and Need Assessment on Pharmaceutical Products in Environmental Waters. http://www.knappe-eu.org/fichiers/47-D5.1%20Ecopharmacostewardship%20disc%20doc. pdf
12. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK (2009) Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A (in press: 10.1021/pr900344m)
13. Connor S. Glaxo chief: Our drugs do not work on most patients. The Independent, Independent News and Media Limited, London, England, 8 December 2003 http: //www.independent.co.uk/news/science/glaxo-chief-our-drugs-do-not- work-on-most-patients-575942.html
14. Constable DJC, Dunn PJ, Hayler JD, Humphrey GR, Leazer JLJ, Linderman RJ, Lorenz K, Manley J, Pearlman Ba, Wells A, Zaks A, Zhang TY (2007) Key Green Chemistry research areas-a perspective from pharmaceutical manufacturers. Green Chem 9, 411-420
15. Costa LG, Eaton DL (eds.) (2005) Gene-Environment Interactions: Fundamentals of Ecogenetics. John Wiley & Sons, Hoboken, NJ
16. Crimmins WF (2001) Disposing of expired drugs: A matter of policy. J Am Vet Med Assoc 218, 10
17. Daemmrich A, Bowden ME (2005) Emergence of pharmaceutical science and industry: 1870-1930. Chem Eng News 83
18. Daughton CG (2002) Environmental stewardship and drugs as pollutants. The Lancet 360, 1035-1036
19. Daughton CG (2003) Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. I. Rationale for and avenues toward a green pharmacy. Environ Health Perspect 111, 757-774
20. Daughton CG (2004) PPCPs in the environment: Future research-beginning with the end always in mind. In: Kümmerer K (ed.) Pharmaceuticals in the Environment: Sources, Fate, Effects and Risks, 2nd edn. Springer, Berlin, Germany
21. Daughton CG (2007) Pharmaceuticals in the environment: Sources and their management. In: Petrovic M, Barcelo D (eds.) Analysis, Fate and Removal of Pharmaceuticals in the Water Cycle. Elsevier Science, Amsterdam
22. Daughton CG (2008) Pharmaceuticals as environmental pollutants: The ramifications for human exposure. In: Heggenhougen K, Quah S (eds.) International Encyclopedia of Public Health. Academic Press, Oxford, England
23. Daughton CG (2009) Chemicals from the practice of healthcare: Challenges and unknowns posed by residues in the environment. Environ Toxicol Chem 28, 2490-2494
24. Daughton CG, Brooks BW (2011-tentative) Pharmaceutical active ingredients in aquatic organisms. In: Beyer WN,Meador J (eds.) Environmental Contaminants in Biota: Interpreting Tissue Concentrations, 2nd edn. Taylor and Francis, Boca Raton, FL
25. Daughton CG, Ruhoy IS (2008) The afterlife of drugs and the role of pharmecovigilance. Drug Safety 31, 1069-1082
26. Daughton CG, Ruhoy IS (2009) Environmental footprint of pharmaceuticals-the significance of factors beyond direct excretion to sewers. Environ Toxicol Chem 28, 2495-2521
27. DBU (2008) Strategies and perspectives for development, use and emission management of pharmaceuticals. 1st International Conference on Sustainable Pharmacy. Osnabrück, Germany, Deutsche Bundesstiftung Umwelt, 24-25 April. http://www.dbu.de/359.html
28. Ebi KL, Kovats RS, Menne B (2006) An approach for assessing human health vulnerability and public health interventions to adapt to climate change. Environ Health Perspect 114, 1930-1934
29. Eckerman I, Martineus J-C (1997) Medicines and the environment-what do we know today? In: Gray M (ed.) Swedish Association of Physicians for the Environment. Stockholm, Sweden. http://www.dnsy.se/-upload/lfm/ medicines%20and%20the%20environment.pdf
30. eHealth Initiative (2008) eHealth Initiative. eHealth Initiative, Foundation for eHealth Initiative. Washington, DC. http://www.ehealthinitiative. org/
31. Ekedahl A (2002) Statistics on local drug sales: A tool to identify problem areas and to follow effects of education on drug use. Doctoral Dissertation, Department of Community Medicine, Malmö University Hospital, Lund University, Lund, Sweden, 54 pp, http://www.lub.lu.se/luft/diss/med638.pdf
32. Fichana D (2005) Green Engineering and Gate-to-gate Life Cycle Assessments for Pharmaceutical Products. Masters Dissertation, Rowan University, 142 pp, http://www.rowan.edu/library//rowan-theses/RU2005/0045GREE.PDF
33. Fugh-Berman A (2009). Speaking of Medicine: Medicine Community Blog, PLoS. http://speakingofmedicine.plos.org/2009/08/07/ghostwriting-101/
34. Galagan Y, Su WF (2008) Fadable ink for time-temperature control of food freshness: Novel new time-temperature indicator. Food Res Int 41, 653-657
35. Giacomini KM, Krauss RM, Roden DM, Eichelbaum M, Hayden MR, Nakamura Y (2007) When good drugs go bad. Nature 446, 975-977
36. Gorard DA (2006) Escalating polypharmacy. QJM 99, 797-800
37. Gunnarsson B, Wennmalm A (2008) Drug design should involve consideration of environmental risk and hazard. Lett Drug Des Discov 5, 232-235
38. HapMap (2008) International HapMap Project. The International HapMap Consortium. http://www.hapmap.org/
39. Haskell SRR, Ormond CJ, Occhipinti LP, Powers EL (2003) Waste management: Expired drugs. J Am Vet Med Assoc 223, 51-52
40. Henderson RK, Jimenez-Gonzalez C, Preston C, Constable DJC,Woodley JM (2008) EHS & LCA assessment for 7-ACA synthesis. A case study for comparing biocatalytic&chemical synthesis. Ind Biotechnol 4, 180-192
41. Hepler C, Strand L (1990) Opportunities and responsibilities in pharmaceutical care. Am J Health Syst Pharm 47, 533-543
42. HHS (2009) Nationwide Health Information Network (NHIN). U.S. Department of Health & Human Services. Washington, DC. http://healthit.hhs.gov/portal/ server.pt?open=512&mode=2&cached=true&objID=1142
43. Hoekstra AY, Chapagain AK (2007)Water footprints of nations:Water use by people as a function of their consumption pattern. Water Resour Manage 21, 35-48
44. Hudson KL, Holohan MK, Collins FS (2008) Keeping pace with the times-the genetic information nondiscrimination act of 2008. N Engl J Med 358, 2661-2663
45. IMS (2008) IMS Health Forecasts 4.5-5.5 Percent Growth for Global Pharmaceutical Market in 2009, Exceeding $820 Billion. IMS Health Incorporated. http://www.imshealth.com/portal/site/imshealth/menuitem. a46c6d4df3db4b3d88f611019418c22a/?vgnextoid= 9e553599b554d110VgnVCM100000ed152ca2RCRD&vgnextfmt=default
46. IOM (2008) Knowing What Works in Health Care: A Roadmap for the Nation. Committee on Reviewing Evidence to Identify Highly Effective Clinical Services, Board on Health Care Services, Institute of Medicine, The National Academies Press, Eden J, Wheatley B,McNeil B, Sox H (ed). Washington, DC. http://www.nap.edu/catalog.php?record-id=12038
47. Joly BM, Polyak G, Davis MV, Brewster J, Tremain B, Raevsky C, Beitsch LM (2007) Linking accreditation and public health outcomes: A logic model approach. J Public Health Manag Pract 13, 349-356
48. Kaitin KI, (ed.) (2005) Drug safety withdrawals in the US not linked to speed of FDA approval. Tufts CSDD (Center for the Study of Drug Development) Impact Report 7, 1-4
49. Katsanis SH, Javitt G, Hudson K (2008) A case study of personalized medicine. Science 320, 53-54
50. Keil F (2008-August) Pharmaceuticals for Human Use: Options of Action for Reducing the Contamination of Water Bodies: A Practical Guide. Institute for Social-Ecological Research (ISOE) GmbH and Research Project start ("Management Strategies for Pharmaceutical Residues in Drinking Water"). Frankfurt/Main, Germany. https://www.start-project.de/downloads/ start-Practical-Guide.pdf
51. Khetan SK, Collins TJ (2007) Human pharmaceuticals in the aquatic environment: A challenge to green chemistry. Chem Rev 107, 2319-2364
52. Korobkin R, Rajkumar R (2008) The genetic information nondiscrimination act-a half-step toward risk sharing. N Engl J Med 359, 335-337
53. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689
54. Kuehn BM (2008) Traces of drugs found in drinking water: Health effects unknown, safer disposal urged. J Am Med Assoc 299, 2011-2013
55. Kümmerer K (2007) Sustainable from the very beginning: Rational design of molecules by life cycle engineering as an important approach for green pharmacy and green chemistry. Green Chem 9, 899-907
56. Kümmerer K, Velo G (2006) Ecopharmacology: A new topic of importance in pharmacovigilance. Drug Saf 29, 371-373
57. Kuspis DA, Krenzelok EP (1996) What happens to expired medications? A survey of community medication disposal. Vet Hum Toxicol 38, 48-49
58. Levy W (2008) Peptide progress: Refined manufacturing and delivery promises more advanced drug offerings. Pharm Formulation & Quality 10, 28-30, 32
59. Markle Foundation (2008) Connecting for Health. The Markle Foundation. http://www.connect-ingforhealth.org/
60. Martin-Calero MJ, Machuca M, Murillo MD, Cansino J, Gastelurrutia MA, Faus MJ (2004) Structural process and implementation programs of pharmaceutical care in different countries. Curr Pharm Des 10, 3969-3985
61. Mayer LD, Janoff AS (2007) Optimizing combination chemotherapy by controlling drug ratios. Mol Interv 7, 216-223
62. Microsoft (2009) Microsoft Amalga Unified Intelligence System 2009. Microsoft. http://www.microsoft.com/amalga/products/microsoftamalgauis/default. mspx
63. Mihelcic JR, Zimmerman JB, Ramaswami A (2007) Integrating developed and developing world knowledge into global discussions and strategies for sustainability. 1. Science and Technology. Environ Sci Technol 41, 3415-3421
64. Moynihan R (2008) Key opinion leaders: Independent experts or drug representatives in disguise? British Medical Journal 336, 1402-1403
65. NIH (2008) NIH Roadmap Initiatives. Office of Portfolio Analysis and Strategic Initiatives, National Institutes of Health Bethesda, Maryland. http://nihroadmap.nih.gov/initiativeslist.asp
66. Patz JA, Campbell-Lendrum D, Holloway T, Foley JA (2005) Impact of regional climate change on human health. Nature 438, 310-317
67. Pearson GJ (2007) Evolution in the practice of pharmacy-not a revolution! CMAJ 176, 1295-1296
68. Phillips DP, Barker GEC, Eguchi MM (2008) A steep increase in domestic fatal medication errors with use of alcohol and/or street drugs. Arch Intern Med 168, 1561-1566
69. Pinheiro C (2008) Drug donations: What lies beneath. Bull World Health Organ 86, 580-581
70. Pollack A. Pricing Pills by the Results. New York Times, New York Times, 14 July 2007 http://www.nytimes.com/2007/07/14/business/14drugprice.html?ref= health&pagewanted=all
71. PricewaterhouseCoopers (2005) Personalized medicine: The emerging pharmacogenomics revolution. PricewaterhouseCoopers GTC, Health Research Institute. http://www.pwc.com/techforecast/pdfs/pharmaco-wb-x.pdf
72. Rahman SZ, Khan RA (2006) Environmental pharmacology: A new discipline. Indian J Pharmacol 38, 229-230
73. Rees WE (1992) Ecological footprints and appropriated carrying capacity: What urban economics leaves out. Environ Urban 4, 121-130
74. Rosenberg J, Schilit S, Nathan J (2008) Which oral solid medications should be protected from light and/or moisture? Drug Topics 12 May, 25-27
75. Ruhoy IS, Daughton CG (2008) Beyond the medicine cabinet: An analysis of where and why medications accumulate. Environ Int 34, 1157-1169
76. SACGHS (May 2008) Realizing the Potential of Pharmacogenomics: Opportunities and Challenges. Secretary's Advisory Committee on Genetics, Health, and Society, chartered by U.S. Department of Health & Human Services (ed). http://www4.od.nih.gov/oba/sacghs/reports/SACGHS-PGx-Report.pdf
77. Sanderson K (2009) Big interest in heavy drugs. Nature 458, 269
78. Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, Khwaja SI, Ahmad N, Cui H, Mousa SA, Mukhtar H (2009) Introducing nanochemoprevention as a novel approach for cancer control: Proof of principle with green tea polyphenol Epigallocatechin-3-Gallate. Cancer Res 69, 1712-1716
79. Sismondo S (2007) Ghost management: How much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med 4, e286
80. Smolensky MH, Peppas NA (2007) Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev 59, 828-851
81. Stockholm City Council (2008) Environmentally Classified Pharmaceuticals. http://www.janusinfo.se/imcms/servlet/GetDoc?meta-id=10205; via www.janusinfo.se/environment
82. Stoughton M, Votta T (2003) Implementing service-based chemical procurement: Lessons and results. J Cleaner Production 11, 839-849
83. Surescripts (2009) 2008 National Progress Report on E-Prescribing. Alexandria, VA: Surescripts LLC. http://www.surescripts.com/downloads/NPR/ national-progress-report.pdf
84. Thayer AM (2008) Filling a highly potent niche: Drug companies want to create conjugates of potent drugs and biological molecules, and custom manufacturers are complying. Chem Eng News 86, 28-32
85. Tinetti ME (2008) Over-the-counter sales of statins and other drugs for asymptomatic conditions. N Engl J Med 358, 2728-2732
86. Trusheim MR, Berndt ER, Douglas FL (2007) Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 6, 287-293
87. Tucker JL (2006) Green chemistry, a pharmaceutical perspective. Org Process Res Dev 10, 315-319
88. Tudor TL (2007) Towards the development of a standardised measurement unit for healthcare waste generation. Resour, Conserv Recycling 50, 319-333
89. UNIDO (2008) Chemical Leasing. United Nations Industrial Development Organization. Vienna, Austria. http://www.chemicalleasing.com/
90. US Congress (24 June 2008) H.R. 6357: PRO(TECH)T Act of 2008 ("Protecting Records, Optimizing Treatment and Easing Communication through Healthcare Technology Act of 2008") 110th Congress, 2D Session, Washington, DC
91. US EPA (2008a) Pharmaceuticals and Personal Care Products (PPCPs): Relevant Literature. US Environmental Protection Agency. http://www.epa.gov/ ppcp/lit.html
92. US EPA (2008b) Green Chemistry Program at EPA. U.S. Environmental Protection Agency. http://www.epa.gov/gcc/pubs/epa-gc.html
93. US FDA (2008a) Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Rockville, MD. http://www.fda.gov/cder/genomics/genomic- biomarkers-table.htm
94. US FDA (2008b) FDA's Sentinel Initiative: National Strategy for Monitoring Medical Product Safety. US Food and Drug Administration. http://www.fda.gov/oc/initiatives/advance/sentinel/
95. van Mil JWF, Schulz M, Tromp TFJD (2004) Pharmaceutical care, European developments in concepts, implementation, teaching, and research: A review. Pharm World & Sci 26, 303-311
96. Venhuis BJ, Barends DM, Zwaagstra ME, de Kaste D (2007) Recent developments in counterfeits and imitations of Viagra, Cialis and Levitra: A 2005-2006 update. RIVM Report 370030001/2007. Bilthoven, the Netherlands: RIVM (Netherlands National Institute for Public Health and the Environment). http://rivm.openrepository.com/rivm/handle/10029/16459?mode=full
97. Warner S (2004) Diagnostics + therapy =theranostics. The Scientist 18, 38
98. White EV, Latif DA (2006) Office-based pharmacy practice: Past, present, and future. Ann Pharmacother 40, 1409-1414
99. WHO (1999) Guidelines for safe disposal of unwanted pharmaceuticals in and after emergencies. World Health Organization. http://www.who.int/water- sanitation-health/medicalwaste/pharmaceuticals/en/index.html
100. WHO (2007) WHO core principles for achieving safe and sustainable management of healthcare waste. World Health Organization, Department for Public Health and Environment, Assessing and Managing Environmental Risks to Health, WHO/SDE/WSH/07.10. http://www.who.int/water-sanitation-health/medicalwaste/ hcwprinciples.pdf; http://www.who.int/water-sanitation-health/medicalwaste/ hcwprinciples/en/index.html
101. WHO (2008a) "World directory of poisons centres (Yellow Tox)" International Programme on Chemical Safety (IPCS). The World Health Organization. Geneva, Switzerland. www.who.int/ipcs/poisons/centre/directory/en/
102. WHO (2008b) About the ATC/DDD system. The WHO Collaborating Centre for Drug Statistics Methodology. Oslo, Norway. http://www.whocc.no/atcddd/atcsystem. html
103. Woodend K (2003) Medication management: The future of pharmaceutical care? Can Pharm J (CPJ) 136, 29-31, 46
104. Woodley JM (2008) New opportunities for biocatalysis:Making pharmaceutical processes greener. Trends Biotechnol 26, 321-327
105. Woodward KN (2005) Veterinary pharmacovigilance. Part 3. Adverse effects of veterinary medicinal products in animals and on the environment. J Vet Pharmacol Therapeut 28, 171-184
106. Zed PJ, Abu-Laban RB, Balen RM, Loewen PS, Hohl CM, Brubacher JR Wilbur K, Wiens MO, Samoy LJ, Lacaria K, Purssell RA (2008) Incidence, severity and preventability of medication-related visits to the emergency department: A prospective study. CMAJ 178, 1563-1569
107. Zuccato E, Calamari D, Natangelo M, Fanelli R (2000) Presence of therapeutic drugs in the environment. The Lancet 355, 1789-1790